EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... December 15, 2020 EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical... October 3, 2025 Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... April 18, 2024 Load more HOT NEWS FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head... Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... Proof of Concept for the Safety and Immunogenicity of Lymph Node...
